Longitudinal Development in Left Ventricular Volume, Mass and Function in Heart Transplant Recipients - Results From the NOCTET Trial
Allograft failure is an important cause of morbidity and mortality in heart transplant recipients. Several reasons for graft dysfunction: hypertension, kidney failure, vasculopathy and allograft hypertrophy, have been attributed to treatment with calcineurin inhibitors. Inhibitors of the mechanistic target of rapamycin (mTOR) may have a more favourable cardiovascular profile. We used data from the randomised, controlled NOCTET trial to assess if treatment with an mTOR-inhibitor attenuates allograft hypertrophy and prevents left ventricular dysfunction.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: K. Broch, R.J. Massey, K. Murbr æch, E. Gude, A.K. Andreassen, L. Gullestad Source Type: research
More News: Bone Graft | Cardiology | Cardiovascular | Heart | Heart Transplant | Hypertension | Kidney Transplant | Kidney Transplantation | Lung Transplant | Transplant Surgery | Transplants | Urology & Nephrology